Mary-Elizabeth Percival

Mary-Elizabeth Percival, MD is an Associate Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine and in the Clinical Research Division at Fred Hutchinson Cancer Center. She practices at Fred Hutchinson Cancer Center and UW Medicine and also serves as an Affiliate Investigator in the Translational Science and Therapeutics Division at Fred Hutch.

Dr. Percival specializes in the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome. Her research focuses on developing early-phase clinical trials for AML patients to test new drugs and drug combinations, as well as conducting epidemiological research to better understand factors affecting survival and outcomes for AML patients.

Her publication record shows consistent research activity in AML, with numerous publications extending from 2013 through 2025, demonstrating her ongoing contributions to the field of hematologic malignancies. Her work spans clinical guidelines, treatment studies, and reviews of diagnostic approaches.

• NCCN Guidelines for AML (2021, 2023)
• Clinical trials for novel AML treatments (2023)
• Studies on transplantation for myelodysplastic syndrome (2023)
• Research on treatment outcomes in refractory AML (2022)
• Diagnostic approaches for AML (2017)

Dr. Percival's work demonstrates a strong focus on improving treatment approaches for patients with acute myeloid leukemia, particularly through clinical trial development and understanding treatment outcomes in various patient populations.